查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1905016

全球連續生物製程市場：依產品、應用、最終用途及地區劃分的分析－市場規模、產業趨勢、機會分析及2026年至2035年預測

Global Continuous Bioprocessing Market: Analysis By Product, Application, End Use, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

連續生物製程市場持續快速擴張，反映出其在生物製藥製造領域日益增長的重要性。 2025年，該市場規模為3.1977億美元，預計到2035年將顯著成長至23.3198億美元。這項預測成長在2026年至2035年的預測期內複合年增長率（CAGR）為21.98%，顯示在多種影響產業的因素支撐下，該市場保持強勁且持續的成長動能。

這一成長的核心在於對提高生物製造製程效率的日益增長的需求。與傳統的間歇式製程相比，連續生物製程具有顯著優勢，能夠實現不間斷生產，減少停機時間，並最大限度地提高產量。這種效率的提昇在複雜生物製劑（例如抗體和疫苗）的生產中尤其重要，因為在這些產品中，保持品質穩定和滿足大批量需求至關重要。更快、更可靠地生產治療藥物，能夠幫助製造商更有效地應對公共衛生需求和市場壓力。

值得關注的市場趨勢

連續生物製程市場由四家公司主導：賽默飛世爾科技 (Thermo Fisher Scientific)、賽多利斯 (Sartorius)、丹納赫 (Danaher)（旗下擁有 CytIV.a 和 Pall 兩大部門）以及默克集團 (Merck KGaA，以 MilliporeSigma 的名義開展業務）。這四家公司共同為產業成長和創新提供了基礎架構。

這些公司提供各種先進的設備、耗材和整合解決方案，幫助生物製藥製造商有效地採用和擴展連續生物製程技術。他們的領先地位源於豐富的專業知識、全球影響力以及致力於開發尖端工具以滿足不斷發展的生物工藝工作流程需求的承諾。

產業內的策略聯盟正在進一步增強連續生物製程的普及勢頭。 2025年12月，全球臨床階段生物製藥公司Transcenta Therapeutics宣布與台灣合約開發和生產機構（CDMO）Irigenix達成重要合作。此次合作包括一項關於Irigenix高度整合連續生物製程（HiCB）平台的非獨家授權協議。

同時，為滿足日益增長的生物製藥及相關生物製程材料需求，生產能力方面的投資也持續擴大。 2025年7月，旭化成生命科學宣布計畫在日本新建一座紡絲工廠，專門生產Planova™病毒去除過濾器。該設施計劃於 2030 年投入運營，屆時將加強關鍵過濾產品的供應，這些產品對於在整個生產過程中維持生物製藥的安全性和純度至關重要。

核心成長驅動因子

全球對疫苗、抗體、生物相似藥以及細胞和基因療法的需求不斷增長，是推動連續生物製程技術應用的關鍵催化劑。隨著全球醫療保健系統面臨越來越大的壓力，需要快速、大規模地提供創新療法，生物製藥製造商正越來越多地轉向連續生物製程技術來應對這些複雜的生產挑戰。這種需求的激增反映了醫療保健行業的更廣泛趨勢，包括慢性病的增加、個人化醫療的進步以及對有效疫苗以對抗新興傳染病的持續需求。

新興機會

對永續性和數位化整合的雙重關注正日益影響著連續生物製程市場，這反映了整個產業向環保和技術先進的生產方法轉變的趨勢。環境責任已不再只是企業社會責任 (CSR) 活動，而已成為一項根本性的業務要務。這項轉變也清楚地體現在產業領導者設定的優先事項中，62% 的生物製藥主管將永續發展列為首要任務。這種高度重視凸顯了永續實踐在塑造產業策略決策和營運方式方面發揮的關鍵作用。

優化障礙

儘管人們對連續生物工藝的採用和發展普遍持樂觀態度，但在充分發揮其潛力方面仍然存在重大挑戰。其中最迫切的挑戰是人才短缺。操作連續生產線需要專門的技能，這與傳統間歇式生產所需的專業知識截然不同。這種轉變對許多尋求採用和擴展這項先進技術的組織構成了重大障礙。

目錄

第一章：摘要整理：全球連續生物工藝市場

第二章：研究方法與架構

  • 研究目標
  • 產品概述
  • 市場區隔
  • 質性研究
    • 一手和二手資料來源
  • 量化研究
    • 一手和二手資料來源
  • 按地區劃分的原始調查受訪者
  • 研究假設
  • 市場規模估算
  • 資料三角驗證

第三章：全球連續生物工藝市場概論

  • 產業價值鏈分析
    • 服務提供者
    • 最終用戶用戶
  • 行業展望
    • 全球研發支出
    • 全球主要生物技術中心（2025 年）
  • PESTLE 分析
  • 波特五力分析
    • 供應商議價能力
    • 買方議價能力
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度
  • 市場成長與展望
    • 市場收入估計與預測（2020-2035 年）
    • 依產品類型劃分的價格趨勢分析
  • 市場吸引力分析
    • 依產品類型劃分
    • 按地區劃分
  • 可操作的洞見（分析師）建議）

第四章：競爭格局概覽

  • 市場集中度
  • 公司佔有率分析（基於價值，2025 年）
  • 競爭格局分析與基準分析

第五章：全球連續生物製程市場分析

  • 市場動態與趨勢
    • 成長驅動因素
    • 限制因素
    • 機遇
    • 關鍵趨勢
  • 市場規模及預測（2020-2035 年）
    • 依產品類型劃分
      • 設備
      • 生物反應器
      • 過濾系統
      • 色譜系統
      • 過程分析技術
      • 其他
      • 耗材和試劑
      • 培養基和緩衝液
      • 過濾器和薄膜
      • 樹脂
      • 試管和試袋
      • 其他
    • 按應用領域
      • 單株抗體
      • 疫苗
      • 細胞和基因治療
      • 研發
      • 其他應用
    • 依最終用途
      • 製藥和生技公司
      • 合約生產組織 (CMO) 和合約研究組織 (CRO)
      • 研究機構和學術機構
    • 按地區

第六章：北美連續生物製程市場分析

第七章：歐洲連續生物製程市場分析

章節第八章：亞太地區連續生物製程市場分析

第九章：中東和非洲連續生物製程市場分析

第十章：南美洲連續生物製程市場分析

第十一章：公司簡介

  • 富士軟片控股株式會社
  • 島津公司
  • Bionet
  • 丹納赫公司
  • Eppendorf SE
  • 默克集團
  • Repligen Corporation
  • 賽多利斯公司
  • 賽默飛世爾科技公司
  • 藥明生物
  • 其他主要企業

第十二章附錄

簡介目錄
Product Code: AA01261635

The continuous bioprocessing market is undergoing rapid expansion, reflecting its increasing importance in the biopharmaceutical manufacturing landscape. Valued at USD 319.77 million in 2025, the market is poised for remarkable growth, with projections estimating it will reach a valuation of USD 2,331.98 million by 2035. This anticipated growth translates to a compound annual growth rate (CAGR) of 21.98% over the forecast period from 2026 to 2035, signaling strong and sustained momentum fueled by multiple factors influencing the industry.

At the core of this growth is the rising demand for greater efficiency in biomanufacturing processes. Continuous bioprocessing offers significant advantages over traditional batch methods by enabling uninterrupted production, which reduces downtime and maximizes output. This efficiency gain is particularly valuable in the production of complex biologics such as antibodies and vaccines, where maintaining consistent quality and meeting high-volume demand are critical. The ability to produce therapies more quickly and reliably allows manufacturers to respond more effectively to public health needs and market pressures.

Noteworthy Market Developments

The continuous bioprocessing market is dominated by four key players-Thermo Fisher Scientific, Sartorius, Danaher (through its Cytiva and Pall divisions), and Merck KGaA (operating as MilliporeSigma)-who collectively provide the essential infrastructure that underpins the industry's growth and innovation.

These companies supply a broad range of advanced equipment, consumables, and integrated solutions that enable biopharmaceutical manufacturers to implement and scale continuous bioprocessing technologies effectively. Their leadership is rooted in extensive expertise, global reach, and a commitment to developing cutting-edge tools that address the evolving needs of bioprocessing workflows.

Strategic collaborations within the industry further reinforce the momentum toward continuous bioprocessing adoption. In December 2025, Transcenta Therapeutics, a global clinical-stage biopharmaceutical company, announced a significant partnership with EirGenix, a Contract Development and Manufacturing Organization (CDMO) based in Taiwan. This collaboration involves a non-exclusive licensing agreement for EirGenix's highly intensified continuous bioprocessing (HiCB) platform.

Meanwhile, investments in manufacturing capacity continue to expand in response to growing demand for biologics and related bioprocessing materials. In July 2025, Asahi Kasei Life Science announced plans to establish a new spinning plant in Japan dedicated to producing Planova(TM) virus removal filters. Scheduled to begin operations in 2030, this facility will enhance the supply of critical filtration products essential for maintaining the safety and purity of biologics throughout their manufacturing processes.

Core Growth Drivers

The rising global demand for vaccines, antibodies, biosimilars, and cell and gene therapies is a significant catalyst driving the adoption of continuous bioprocessing technologies. As healthcare systems worldwide face mounting pressure to deliver innovative treatments rapidly and at scale, biopharmaceutical manufacturers are increasingly turning to continuous bioprocessing to meet these complex production challenges. This surge in demand reflects broader trends in medicine, including the growing prevalence of chronic diseases, advancements in personalized therapies, and the ongoing need for effective vaccines to combat emerging infectious diseases.

Emerging Opportunity Trends

The continuous bioprocessing market is increasingly influenced by a dual emphasis on sustainability and digital integration, reflecting broader industry shifts toward environmentally responsible and technologically advanced manufacturing practices. Environmental responsibility has transcended being a mere corporate social responsibility initiative and has become a fundamental business imperative. This shift is evident in the priorities set by industry leaders, with a striking 62% of biopharma executives identifying sustainability as their foremost concern. Such a strong focus underscores the critical role that sustainable practices play in shaping strategic decisions and operational approaches within the sector.

Barriers to Optimization

Despite the widespread optimism surrounding the adoption and advancement of continuous bioprocessing, significant challenges continue to hinder its full potential. Among these, the most pressing issue is the talent gap within the workforce. Operating continuous manufacturing lines demands a specialized skillset that differs substantially from the expertise required for traditional batch processing. This transition poses a significant obstacle for many organizations as they strive to implement and scale these advanced technologies.

Detailed Market Segmentation

By Product, the consumables and reagents segment dominated the continuous bioprocessing market. This reflects its critical role in maintaining seamless and sterile operations within biomanufacturing processes. These consumables, which include single-use components such as filters, tubing, bags, and various reagents, are essential for ensuring that bioprocessing environments remain contamination-free and that product integrity is preserved throughout production. The reliance on disposable materials helps eliminate cross-contamination risks that can occur with reusable equipment, making them indispensable in continuous manufacturing systems that require stringent sterility standards.

By Application, the monoclonal antibody (mAb) segment maintains a dominant position in the continuous bioprocessing market. Monoclonal antibodies have become a cornerstone of modern therapeutics, widely used to treat a variety of diseases, including cancers, autoimmune disorders, and infectious diseases. Their proven efficacy and growing demand have driven sustained investment and innovation within this application segment, reinforcing its leadership in the bioprocessing landscape.

By End Use, the pharmaceutical and biotechnology segment continues to serve as the undisputed driving force behind the growth of the continuous bioprocessing market. This sector's strong demand for efficient, scalable, and flexible production methods has positioned it at the forefront of adopting continuous bioprocessing technologies. Unlike traditional approaches that rely on batch processing, continuous bioprocessing offers significant advantages such as reduced production times, improved product consistency, and enhanced cost efficiency-all critical factors for pharmaceutical and biotech companies aiming to meet growing global demand for innovative therapies.

Segment Breakdown

By Product

  • Instruments
  • Bioreactors
  • Filtration Systems
  • Chromatography Systems
  • Process Analytical Technologies
  • Others
  • Consumables & Reagents
  • Media & Buffers
  • Filters & Membranes
  • Resin
  • Tubing & Bags
  • Others

By Application

  • Monoclonal antibodies
  • Vaccines
  • Cell and gene therapy
  • Research & Development
  • Other applications

By End Use

  • Pharmaceutical and biotechnology companies
  • CMOs and CROs
  • Research and academic institutes

By Region

  • North America
  • The US
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a commanding 39% share of the global continuous bioprocessing market, solidifying its position as the epicenter of innovation and adoption in this rapidly evolving sector. This leadership is the result of a combination of strategic investments, advanced technological capabilities, and a supportive regulatory environment that together foster an ecosystem conducive to growth and development. The region's dominance reflects its ability to pioneer new bioprocessing techniques and implement them at scale, setting benchmarks for the industry worldwide.
  • A key factor underpinning North America's market leadership is the aggressive capital deployment by major pharmaceutical and biotech players. For example, Sanofi's commitment to invest USD 20 billion in manufacturing and research and development across the United States through 2030 exemplifies the scale of financial resources being directed toward advancing continuous bioprocessing technologies.
  • Regulatory confidence further strengthens the region's dominance in the continuous bioprocessing market. The U.S. Food and Drug Administration (FDA) plays a crucial role by fostering a regulatory environment that encourages innovation while ensuring safety and efficacy. In 2024 alone, the FDA approved 48 novel drugs, signaling robust support for new therapies and the processes that bring them to market.

Leading Market Participants

  • FUJIFILM HOLDINGS CORPORATION
  • Shimadzu Corporation
  • Bionet
  • Danaher Corporation
  • Eppendorf SE
  • Merck KGaA
  • Repligen Corporation
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Continuous Bioprocessing Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Continuous Bioprocessing Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Service Provider
    • 3.1.2. End Consumers
  • 3.2. Industry Outlook
    • 3.2.1. Global R&D Expenditure
    • 3.2.2. Top Biotechnology Hubs in the World, 2025
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Product Type
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Product Type
    • 3.6.2. By Region
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Continuous Bioprocessing Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Instruments
          • 5.2.1.1.1.1. Bioreactors
          • 5.2.1.1.1.2. Filtration Systems
          • 5.2.1.1.1.3. Chromatography Systems
          • 5.2.1.1.1.4. Process Analytical Technologies
          • 5.2.1.1.1.5. Others
        • 5.2.1.1.2. Consumables & Reagents
          • 5.2.1.1.2.1. Media & Buffers
          • 5.2.1.1.2.2. Filters & Membranes
          • 5.2.1.1.2.3. Resin
          • 5.2.1.1.2.4. Tubing & Bags
          • 5.2.1.1.2.5. Others
    • 5.2.2. By Application
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Monoclonal antibodies
        • 5.2.2.1.2. Vaccines
        • 5.2.2.1.3. Cell and gene therapy
        • 5.2.2.1.4. Research & Development
        • 5.2.2.1.5. Other applications
    • 5.2.3. By End Use
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Pharmaceutical and biotechnology companies
        • 5.2.3.1.2. CMOs and CROs
        • 5.2.3.1.3. Research and academic institutes
    • 5.2.4. By Region
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. North America
          • 5.2.4.1.1.1. The U.S.
          • 5.2.4.1.1.2. Canada
          • 5.2.4.1.1.3. Mexico
        • 5.2.4.1.2. Europe
          • 5.2.4.1.2.1. Western Europe
            • 5.2.4.1.2.1.1. The UK
            • 5.2.4.1.2.1.2. Germany
            • 5.2.4.1.2.1.3. France
            • 5.2.4.1.2.1.4. Italy
            • 5.2.4.1.2.1.5. Spain
            • 5.2.4.1.2.1.6. Rest of Western Europe
          • 5.2.4.1.2.2. Eastern Europe
            • 5.2.4.1.2.2.1. Poland
            • 5.2.4.1.2.2.2. Russia
            • 5.2.4.1.2.2.3. Rest of Eastern Europe
        • 5.2.4.1.3. Asia Pacific
          • 5.2.4.1.3.1. China
          • 5.2.4.1.3.2. India
          • 5.2.4.1.3.3. Japan
          • 5.2.4.1.3.4. South Korea
          • 5.2.4.1.3.5. Australia & New Zealand
          • 5.2.4.1.3.6. ASEAN
              • 5.2.4.1.3.6.1.1. Indonesia
              • 5.2.4.1.3.6.1.2. Malaysia
              • 5.2.4.1.3.6.1.3. Thailand
              • 5.2.4.1.3.6.1.4. Singapore
              • 5.2.4.1.3.6.1.5. Rest of ASEAN
          • 5.2.4.1.3.7. Rest of Asia Pacific
        • 5.2.4.1.4. Middle East & Africa
          • 5.2.4.1.4.1. UAE
          • 5.2.4.1.4.2. Saudi Arabia
          • 5.2.4.1.4.3. South Africa
          • 5.2.4.1.4.4. Rest of MEA
        • 5.2.4.1.5. South America
          • 5.2.4.1.5.1. Argentina
          • 5.2.4.1.5.2. Brazil
          • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Continuous Bioprocessing Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End Use
    • 6.2.4. By Country

Chapter 7. Europe Continuous Bioprocessing Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End Use
    • 7.2.4. By Country

Chapter 8. Asia Pacific Continuous Bioprocessing Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End Use
    • 8.2.4. By Country

Chapter 9. Middle East & Africa Continuous Bioprocessing Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End Use
    • 9.2.4. By Country

Chapter 10. South America Continuous Bioprocessing Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End Use
    • 10.2.4. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. FUJIFILM HOLDINGS CORPORATION
  • 11.2. Shimadzu Corporation
  • 11.3. Bionet
  • 11.4. Danaher Corporation
  • 11.5. Eppendorf SE
  • 11.6. Merck KGaA
  • 11.7. Repligen Corporation
  • 11.8. Sartorius AG
  • 11.9. Thermo Fisher Scientific Inc.
  • 11.10. WuXi Biologics
  • 11.11. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Leather Types
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators